NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Purchases 7,798 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 7,798 shares of the firm’s stock in a transaction dated Monday, July 27th. The stock was acquired at an average price of $5.00 per share, for a total transaction of $38,990.00. Following the purchase, the insider owned 383,456 shares in the company, valued at approximately $1,917,280. The trade was a 2.08% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The shares were acquired at an average cost of $5.00 per share, with a total value of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The shares were acquired at an average price of $4.95 per share, with a total value of $31,680.00.

NextCure Price Performance

NASDAQ:NXTC traded down $0.40 during trading hours on Wednesday, hitting $5.02. The company’s stock had a trading volume of 355,456 shares, compared to its average volume of 939,730. NextCure, Inc. has a twelve month low of $1.55 and a twelve month high of $15.74. The stock has a fifty day simple moving average of $3.76 and a 200-day simple moving average of $8.83. The company has a market capitalization of $18.12 million, a P/E ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, equities analysts predict that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Institutional Trading of NextCure

Several large investors have recently made changes to their positions in NXTC. Affinity Asset Advisors LLC increased its position in NextCure by 28.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares in the last quarter. Ikarian Capital LLC bought a new position in NextCure in the fourth quarter worth approximately $3,382,000. Squadron Capital Management LLC acquired a new stake in NextCure in the fourth quarter valued at approximately $3,363,000. Exome Asset Management LLC acquired a new stake in NextCure in the fourth quarter valued at approximately $2,341,000. Finally, AWM Investment Company Inc. bought a new stake in shares of NextCure during the fourth quarter valued at approximately $1,665,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NXTC has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of NextCure in a research note on Wednesday, July 15th. Finally, Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, NextCure has a consensus rating of “Hold” and an average price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.